BRAF and non-small cell lung carcinoma: Dabrafenib plus trametinib is the standard treatment for patients with mutant metastatic NSCLC with BRAF V600E mutations; in a phase II trial, the median progression-free survival time was 14.6 months in treatment-naïve patients [16].